Table 4.

Comparison of the 11-protein signature with currently applied clinical consensus criteria on treatment of breast cancer

Method	Patients guided to receive adjuvant chemotherapy in the test set
	Poor prognosis	Good prognosis
St. Gallen*	18/18 (100%)‡	40/44 (91%)
NIH†	14/17 (82%)‡	38/40 (95%)‡
11-protein signature	17/19 (89%)	13/44 (30%)§

* St. Gallen consensus criteria: tumor ≥2cm, ESR1 negative, grade 2–3, patient aged <35 years (one of these criteria).

† National Institutes of Health (NIH) guideline: tumor >1cm.

‡ Patients with missing clinical information were excluded from these analyses.

§ A statistically significant improvement.